Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Denmark-based NeuroSearch has dosed the first healthy volunteers in a clinical Phase I study with NSD-788 with a view to developing this drug candidate as a new treatment for anxiety and depression.
Subscribe to our email newsletter
The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study to evaluate the compound’s safety, tolerability and pharmacokinetic profile after oral administration.
The study is being performed in France. Based on studies in preclinical models, NeuroSearch believes that NSD-788 may show significant advantages over existing drugs for the treatment of anxiety, but also of other CNS disorders. NeuroSearch is performing the first phases of the clinical development of NSD-788 with a view to studying the compound’s anxiolytic properties and with special focus on certain specialist CNS indications.
Flemming Pedersen, CEO of NeuroSearch, said: “With the initiation of this Phase I study with NSD-788, NeuroSearch has now initiated three clinical programs with new drug candidates within the past six months.”